These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 10499639)

  • 1. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
    Mizutani Y; Yoshida O; Miki T; Bonavida B
    Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
    Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
    J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
    Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D.
    Mori S; Murakami-Mori K; Nakamura S; Ashkenazi A; Bonavida B
    J Immunol; 1999 May; 162(9):5616-23. PubMed ID: 10228045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS; Kemp TJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity.
    Mizutani Y; Okada Y; Yoshida O; Fukumoto M; Bonavida B
    Cancer; 1997 Mar; 79(6):1180-9. PubMed ID: 9070496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
    Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
    J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.
    Mizutani Y; Nakanishi H; Yoshida O; Fukushima M; Bonavida B; Miki T
    Eur J Cancer; 2002 Jan; 38(1):167-76. PubMed ID: 11750847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
    Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
    Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity.
    Johnsen AC; Haux J; Steinkjer B; Nonstad U; Egeberg K; Sundan A; Ashkenazi A; Espevik T
    Cytokine; 1999 Sep; 11(9):664-72. PubMed ID: 10479402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL and chemotherapeutic drugs in cancer therapy.
    Wu XX; Ogawa O; Kakehi Y
    Vitam Horm; 2004; 67():365-83. PubMed ID: 15110186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.